THIRTY DAY CLINICAL OUTCOMES FOLLOWING IMPLEMENTATION OF CYP2C19 GENOTYPE-GUIDED DUAL ANTIPLATELET THERAPY

Authors :: Nicholas Varunok
George A. Stouffer
Alexandra Cervantes
Vindhya B. Sriramoju
Craig R. Lee
Melissa D. Klein
Shivanshu Madan
Karen E. Weck
Source :: Journal of the American College of Cardiology. 71:A1196
Publication Year :: 2018
Publisher :: Elsevier BV, 2018.
Abstract: The clinical impact of using CYP2C19 genotype to guide dual antiplatelet therapy (DAPT) after percutaneous coronary intervention (PCI) remains unclear. This single center retrospective cohort study included 1193 PCI patients from 2012-14. CYP2C19 genotyping was recommended in high risk patients

Subjects :: medicine.medical_specialty
business.industry
medicine.medical_treatment
Cyp2c19 genotype
Percutaneous coronary intervention
Retrospective cohort study
CYP2C19
Single Center
surgical procedures, operative
Internal medicine
THIRTY-DAY
Conventional PCI
medicine
cardiovascular diseases
Cardiology and Cardiovascular Medicine
business
Genotyping

Full Text Access

Tools